A genetic clue uncovered by scientists enables doctors to predict, for the first time, which children with T-cell acute lymphoblastic leukemia (T-ALL) are unlikely to benefit from standard chemotherapy for the disease and should therefore be among the first to receive new treatments in future clinical trials.

• Previous Entry: Concierge medicine offers personalized care, but not without controversy
• Next Entry: Graphene oxide gets green: Environmentally friendly ways to make it in bulk, break it down